HK1212698A1 - Thiazolyl- and oxazolyl-isoquinolinones and methods for using them - Google Patents

Thiazolyl- and oxazolyl-isoquinolinones and methods for using them Download PDF

Info

Publication number
HK1212698A1
HK1212698A1 HK16100665.6A HK16100665A HK1212698A1 HK 1212698 A1 HK1212698 A1 HK 1212698A1 HK 16100665 A HK16100665 A HK 16100665A HK 1212698 A1 HK1212698 A1 HK 1212698A1
Authority
HK
Hong Kong
Prior art keywords
compound
isoquinolin
hydroxy
thiazolo
pharmaceutically acceptable
Prior art date
Application number
HK16100665.6A
Other languages
English (en)
Chinese (zh)
Inventor
Roberto Pellicciari
Flavio Moroni
Adam M Gilbert
Original Assignee
Roberto Pellicciari
Flavio Moroni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Pellicciari, Flavio Moroni filed Critical Roberto Pellicciari
Publication of HK1212698A1 publication Critical patent/HK1212698A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK16100665.6A 2008-06-19 2016-01-21 Thiazolyl- and oxazolyl-isoquinolinones and methods for using them HK1212698A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7385708P 2008-06-19 2008-06-19
US73857P 2008-06-19

Publications (1)

Publication Number Publication Date
HK1212698A1 true HK1212698A1 (en) 2016-06-17

Family

ID=41087350

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100665.6A HK1212698A1 (en) 2008-06-19 2016-01-21 Thiazolyl- and oxazolyl-isoquinolinones and methods for using them

Country Status (12)

Country Link
US (3) US8299090B2 (enExample)
EP (2) EP2303895B1 (enExample)
JP (2) JP5564495B2 (enExample)
AR (1) AR072265A1 (enExample)
AU (1) AU2009260060B2 (enExample)
CA (1) CA2728454C (enExample)
DK (1) DK2303895T3 (enExample)
ES (1) ES2530815T3 (enExample)
HK (1) HK1212698A1 (enExample)
SA (1) SA109300394B1 (enExample)
TW (1) TWI471329B (enExample)
WO (1) WO2009155402A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA109300394B1 (ar) 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
CA2728466A1 (en) 2008-06-19 2009-12-23 Wyeth Llc Thienyl- and furanyl-isoquinolinones and methods for using them
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
KR20140036312A (ko) * 2011-07-13 2014-03-25 산텐 세이야꾸 가부시키가이샤 Ｐａｒｐ 저해 활성을 갖는 신규 화합물
LT3325623T (lt) 2015-07-23 2019-10-25 Inst Curie Dbait molekulės ir parp inhibitorių derinio panaudojimas vėžiui gydyti
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005745B1 (en) * 1978-05-26 1982-07-14 Gruppo Lepetit S.P.A. Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
ATE540928T1 (de) * 2002-11-22 2012-01-15 Mitsubishi Tanabe Pharma Corp Isochinolinverbindungen und ihre medizinische verwendung
WO2007014907A1 (en) 2005-08-01 2007-02-08 Wietek Holding Gmbh Process for the recycling of plastics
EP2069351B1 (en) * 2006-06-20 2015-10-28 AbbVie Inc. Pyrazoloquinazolinones as parp inhibitors
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
CA2728466A1 (en) * 2008-06-19 2009-12-23 Wyeth Llc Thienyl- and furanyl-isoquinolinones and methods for using them

Also Published As

Publication number Publication date
WO2009155402A1 (en) 2009-12-23
SA109300394B1 (ar) 2013-01-22
HK1156310A1 (en) 2012-06-08
AU2009260060B2 (en) 2015-01-22
US8906935B2 (en) 2014-12-09
US20150133443A1 (en) 2015-05-14
JP2011525185A (ja) 2011-09-15
EP2896626A1 (en) 2015-07-22
DK2303895T3 (en) 2015-01-12
US20090318442A1 (en) 2009-12-24
TWI471329B (zh) 2015-02-01
JP2014122242A (ja) 2014-07-03
US8299090B2 (en) 2012-10-30
ES2530815T3 (es) 2015-03-05
CA2728454C (en) 2017-01-17
US9265769B2 (en) 2016-02-23
EP2303895B1 (en) 2014-09-24
AU2009260060A1 (en) 2009-12-23
JP5564495B2 (ja) 2014-07-30
EP2303895A1 (en) 2011-04-06
TW201002725A (en) 2010-01-16
AR072265A1 (es) 2010-08-18
US20130059843A1 (en) 2013-03-07
CA2728454A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
US8906935B2 (en) Thiazolyl- and oxazolyl-isoquinolinones and methods for using them
CA3213029A1 (en) Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
EA016079B1 (ru) Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
US11981681B2 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
US20040063665A1 (en) Substituted benzopyranones as telomerase inhibitors
EP2313418B1 (en) Thienyl- and furanyl-isoquinolinones and methods for using them
HK1156310B (en) Thiazolyl- and oxazolyl-isoquinolinones and methods for using them
CN114671856A (zh) 多取代的尿嘧啶衍生物及其用途
CN121219288A (zh) 用于治疗疾病或障碍的萘啶酮衍生物
HK40069843B (en) Estrogen-related receptor alpha (erralpha) modulators
HK40069843A (en) Estrogen-related receptor alpha (erralpha) modulators
HK40039957A (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
HK40039957B (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors